

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> Date Submitted: February 19, 2004 (use as many sheets as necessary)		<b>Complete if Known</b>	
		Reissue Patent Number	6,348,481
		Grant Date	February 19, 2002
		First Named Inventor	Yoshiyuki INADA, et al.
		Group Art Unit	1626
		Examiner Name	Deborah C. Lambkin
		Attorney Docket Number	087147-0450
Sheet	1	of	1

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
<i>DL</i>	A1	Wada et al., "Combined Effects of the Angiotensin II Antagonist Candesartan Cilexetil (TCV-116) and Other Classes of Antihypertensive Drugs in Spontaneously Hypertensive Rats," Hypertens. Res., vol. 19, no. 4, pages 247-254 (1996).	
<i>DL</i>	A2	Sleight, "Cardiac Benefits of ACE Inhibitors and Calcium Antagonists Alone and in Combination," J. Cardiovasc. Pharmacol., Vol. 23, Supp. 1, pages S39-S42 (1994).	
<i>DL</i>	A3	Nagao, "Calcium Entry Blockers: Antihypertensive and Natriuretic Effects in Experimental Animals," Am. J. Cardiol., vol. 56, no. 16, pages 56H-61H (1985) (ABSTRACT ONLY).	
<i>DL</i>	A4	Sato et al., "Role of Angiotensin II in Reflex Tachycardia During Hypotension Caused by a Calcium Channel Blocker," Clin. And Exper. Hypertension, Vol. 18, no. 5, pages 607-624 (1996).	

Examiner Signature	<i>D. Lambkin</i>	Date Considered	<i>9/14/04</i>
-----------------------	-------------------	--------------------	----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.